Eli Lilly and Company

Correction d’un communiqué du 23.10.2019, 17:55 CET/CEST – Eli Lilly and Company: Q319LillySalesandEarningsPressRelease

Eli Lilly and Company: Q319LillySalesandEarningsPressRelease

Eli Lilly and Company: Lilly Reports Strong Third-Quarter 2019 Financial Results, Raises 2019 EPS Guidance

Eli Lilly and Company: Files Form 3 and 4

Eli Lilly and Company: Lilly Announces Voluntary Delisting from Euronext Paris

Eli Lilly and Company: Eli Lilly and Company Files 10-Q

Eli Lilly and Company: Eli Lilly and Company Files 8-K

Eli Lilly and Company: Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance

Eli Lilly and Company: Eli Lilly and Company Files Form 4

Eli Lilly and Company: Lilly Declares Third-Quarter 2019 Dividend

Eli Lilly and Company: Eli Lilly and Company Files 8-K

Eli Lilly and Company: Eli Lilly and Company Files 10-Q

Eli Lilly and Company: Eli Lilly and Company Files 8-K

Eli Lilly and Company: Lilly Reports Solid First-Quarter 2019 Financial Results, Updates 2019 Guidance to Reflect Disposition of Elanco Animal Health

Eli Lilly and Company: ELI LILLY AND COMPANY FILES FORM 3, FORM 4, and FORM 5

Eli Lilly and Company: Eli Lilly and Company calls company stockholders meeting

Eli Lilly and Company: Eli Lilly and Company Files Preliminary Proxy

Eli Lilly and Company: Eli Lilly and Company Files 10-K

Eli Lilly and Company: Eli Lilly and Company Announces Plan for Divestiture of its Remaining Interest in Elanco Animal Health

Eli Lilly and Company: Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology

Eli Lilly and Company: Eli Lilly and Company files 8-K

Eli Lilly and Company: Eli Lilly and Company files 8-K

Eli Lilly and Company: Lilly Announces Agreement To Acquire Loxo Oncology

Eli Lilly and Company: Eli Lilly and Company Files 8-K

Eli Lilly and Company: Lilly Announces Financial Guidance, Reviews Commercial Performance, and Highlights Promising Pipeline Opportunities at Investment Community Meeting

Eli Lilly and Company: Lilly Announces 15 Percent Dividend Increase

Eli Lilly and Company: Eli Lilly and Company Files an 8-K

Eli Lilly and Company: Eli Lilly and Company Files 10-Q

Eli Lilly and Company: Eli Lilly and Company Files Form 8-K

Eli Lilly and Company: Lilly Delivers Solid Third-Quarter 2018 Results, Revises EPS Guidance